Tumour size measurement in a mouse model using high resolution MRI

BMC Medical Imaging

Eva Forssell-Aronsson³  Michael Horn²  Maria Ljungberg³  Mikael Montelius¹ 

[1] Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Centre, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, SE-413 45, Sweden;Department of Radiology, University of Würzburg, Würzburg, Germany;Division of Medical Physics and Medical Engineering, Sahlgrenska University Hospital, Gothenburg, SE-413 45, Sweden

关键词: Cancer;    Volume determination;    Magnetic resonance;    Animal model;   

Others  :  1092162
DOI  :  10.1186/1471-2342-12-12

 received in 2011-06-08, accepted in 2012-05-15,  发布年份 2012

【 摘 要 】

Background

Animal models are frequently used to assess new treatment methods in cancer research. MRI offers a non-invasive in vivo monitoring of tumour tissue and thus allows longitudinal measurements of treatment effects, without the need for large cohorts of animals. Tumour size is an important biomarker of the disease development, but to our knowledge, MRI based size measurements have not yet been verified for small tumours (10⁻²–10⁻¹ g). The aim of this study was to assess the accuracy of MRI based tumour size measurements of small tumours on mice.

Methods

2D and 3D T2-weighted RARE images of tumour bearing mice were acquired in vivo using a 7 T dedicated animal MR system. For the 3D images the acquired image resolution was varied. The images were exported to a PC workstation where the tumour mass was determined assuming a density of 1 g/cm³, using an in-house developed tool for segmentation and delineation. The resulting data were compared to the weight of the resected tumours after sacrifice of the animal using regression analysis.

Results

Strong correlations were demonstrated between MRI- and necropsy determined masses. In general, 3D acquisition was not a prerequisite for high accuracy. However, it was slightly more accurate than 2D when small (<0.2 g) tumours were assessed for inter- and intraobserver variation. In 3D images, the voxel sizes could be increased from 160³ μm³ to 240³ μm³ without affecting the results significantly, thus reducing acquisition time substantially.

Conclusions

2D MRI was sufficient for accurate tumour size measurement, except for small tumours (<0.2 g) where 3D acquisition was necessary to reduce interobserver variation. Acquisition times between 15 and 50 minutes, depending on tumour size, were sufficient for accurate tumour volume measurement. Hence, it is possible to include further MR investigations of the tumour, such as tissue perfusion, diffusion or metabolic composition in the same MR session.

【 授权许可】

   
2012 Montelius et al. licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Maecke HR, Forssell-Aronsson E: Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-Octreotate in an Animal Model. J Nucl Med 2004, 45(9):1542-1548.
• [2]Masciotti J, Provenzano F, Papa J, Klose A, Hur J, Gu X, Yamashiro D, Kandel J, Hielscher A: Monitoring Tumor Growth and Treatment in Small Animals with Magnetic Resonance and Optical Tomographic Imaging. In Proceedings of SPIE: 21 January 2006; San Jose. Edited by Fred S. Azar, Dimitris N, Metaxas; 2006:608105-1.
• [3]Kölby L, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Forssell-Aronsson E, Macke H, Nilsson O: Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 2005, 93(10):1144-1151.
• [4]Tomayko M, Reynolds C: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer chemotherapy and pharmacology 1989, 24(3):148-154.
• [5]Euhus DM, Hudd C, Laregina MC, Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol 1986, 31(4):229-234.
• [6]He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius VK, Sarkar FH: Magnetic Resonance Imaging to Measure Therapeutic Response Using an Orthotopic Model of Human Pancreatic Cancer. Pancreas 2000, 21(1):69-76.
• [7]Mazurchuk R, Glaves D, Raghavan D: Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. Clin Cancer Res 1997, 3(9):1635-1641.
• [8]Grimm J, Potthast A, Wunder A, Moore A: Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer 2003, 106(5):806-811.
• [9]Partecke I, Kaeding A, Sendler M, Albers N, Kuhn J-P, Speerforck S, Roese S, Seubert F, Diedrich S, Kuehn S, et al.: In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer 2011, 11(1):40. BioMed Central Full Text
• [10]Forssell-Aronsson E, Kjellén E, Mattsson S, Hellström M, Swedish Cancer Society Investigation Group T: Medical Imaging for Improved Tumour Characterization, Delineation and Treatment Verification. Acta Oncologica 2002, 41(7):604-614.
• [11]Weissleder R: Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002, 2(1):11-18.
• [12]Jensen M, Jorgensen J, Binderup T, Kjaer A: Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18 F-FDG-microPET or external caliper. BMC Medical Imaging 2008, 8(1):16. BioMed Central Full Text
• [13]Sorensen AG: Magnetic Resonance As a Cancer Imaging Biomarker. J Clin Oncol 2006, 24(20):3274-3281.
• [14]De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J: Magnetic resonance imaging of soft tissue tumors. Eur Radiol 2000, 10(2):213-223.
• [15]Low RN: Abdominal MRI advances in the detection of liver tumours and characterisation. The Lancet Oncology 2007, 8(6):525-535.
• [16]Hakumäki JM, Brindle KM: Techniques: Visualizing apoptosis using nuclear magnetic resonance. Trends Pharmacol Sci 2003, 24(3):146-149.
• [17]Raman V, Pathak AP, Glunde K, Artemov D, Bhujwalla ZM: Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed 2007, 20(3):186-199.
• [18]Kettunen MI, Brindle KM: Apoptosis detection using magnetic resonance imaging and spectroscopy. Prog Nucl Magn Reson Spectrosc 2005, 47(3–4):175-185.
• [19]Barrett T, Brechbiel M, Bernardo M, Choyke PL: MRI of tumor angiogenesis. J Magn Reson Imaging 2007, 26(2):235-249.
• [20]Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, Kloetzer K-H, Marx C: Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer? Int J Radiat Biol 2009, 85(9):814-824.
• [21]Pacheco-Torres J, López-Larrubia P, Ballesteros P, Cerdán S: Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed 2011, 24(1):1-16.
• [22]Hennig J, Nauerth A, Friedburg H: RARE imaging: A fast imaging method for clinical MR. Magn Reson Med 1986, 3(6):823-833.
• [23]Crémillieux Y, Ding S, Dunn JF: High-resolution in vivo measurements of transverse relaxation times in rats at 7 Tesla. Magn Reson Med 1998, 39(2):285-290.
• [24]Frost C, Thompson SG: Correcting for regression dilution bias: comparison of methods for a single predictor variable. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2000, 163(2):173-189.